Annie Kennedy

1.1k total citations · 2 hit papers
23 papers, 633 citations indexed

About

Annie Kennedy is a scholar working on Molecular Biology, Genetics and Psychiatry and Mental health. According to data from OpenAlex, Annie Kennedy has authored 23 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Genetics and 5 papers in Psychiatry and Mental health. Recurrent topics in Annie Kennedy's work include Muscle Physiology and Disorders (8 papers), Neurogenetic and Muscular Disorders Research (8 papers) and Adolescent and Pediatric Healthcare (4 papers). Annie Kennedy is often cited by papers focused on Muscle Physiology and Disorders (8 papers), Neurogenetic and Muscular Disorders Research (8 papers) and Adolescent and Pediatric Healthcare (4 papers). Annie Kennedy collaborates with scholars based in United States, France and Canada. Annie Kennedy's co-authors include Kathi Kinnett, Elisabeth Oehrlein, Natalie Street, Garey Noritz, Christina Trout, Jamie Sullivan, Carla Bann, K. Bushby, Angela Glover Blackwell and Anne Pariser and has published in prestigious journals such as Neurology, PEDIATRICS and Cancer Research.

In The Last Decade

Annie Kennedy

21 papers receiving 607 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan

2018 278 citations David J. Birnkrant, K. Bushby et al. The Lancet Neurology profile →
The national economic burden of rare disease in the United States in 2019

2022 98 citations Inna Cintina, Anne Pariser et al. Orphanet Journal of Rare Diseases profile →

Peers

Countries citing papers authored by Annie Kennedy

Since Specialization

Citations

This map shows the geographic impact of Annie Kennedy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Kennedy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Kennedy more than expected).

Fields of papers citing papers by Annie Kennedy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Kennedy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Kennedy. The network helps show where Annie Kennedy may publish in the future.

Co-authorship network of co-authors of Annie Kennedy

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Kennedy. A scholar is included among the top collaborators of Annie Kennedy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Kennedy. Annie Kennedy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues 2025 ·Journal of Managed Care & Specialty Pharmacy ·Colin M. Young, (unknown), Annie Kennedy, Jamie Sullivan, Bernie McGowan, Mark Trusheim	0
2	Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies 2024 ·Journal of Multidisciplinary Healthcare ·Ryan Fischer, (unknown), Annie Kennedy, (unknown), (unknown), (unknown), (unknown), Linda Lowes, Nancy L. Kuntz, Perry B. Shieh, Jane Kondejewski, Peter J. Neumann, Jason Shafrin, Richard J. Willke	2
3	The Early Care (0–3 Years) In Duchenne Muscular Dystrophy Meeting Report 2024 ·Journal of Neuromuscular Diseases ·(unknown), Susan Apkon, Kiera N. Berggren, (unknown), Emma Ciafaloni, Anne M. Connolly, Annie Kennedy, Nancy L. Kuntz, Katherine D. Mathews, (unknown), Richard B. Parad, Mena Scavina, Rebecca J. Scharf, Megan A. Waldrop	2
4	Expediting treatments in the 21st century: orphan drugs and accelerated approvals 2024 ·Orphanet Journal of Rare Diseases ·(unknown), G. K. Raju, Jamie Sullivan, Annie Kennedy	0
5	Are we prepared to deliver gene‐targeted therapies for rare diseases? 2023 ·American Journal of Medical Genetics Part C Seminars in Medical Genetics ·Timothy W. Yu, Stephen F. Kingsmore, Robert C. Green, Tippi C. MacKenzie, Melissa Wasserstein, Michele Caggana, Nina B. Gold, Annie Kennedy, Priya S. Kishnani, Matthew Might, Philip J. Brooks, Jill A. Morris, Melissa A. Parisi, Tiina K. Urv	9
6	Common Challenges and Identified Solutions for State Newborn Screening Programs during COVID-19 Pandemic 2022 ·International Journal of Neonatal Screening ·(unknown), (unknown), Mei Baker, Amy Gaviglio, Dorota Gruber, (unknown), Norma P. Tavakoli, Jamie Sullivan, Annie Kennedy	4
7	Patient-Centered Core Impact Sets: What They are and Why We Need Them 2022 ·Patient ·Eleanor M. Perfetto, Elisabeth Oehrlein, (unknown), (unknown), Annie Kennedy, (unknown)	11
8	The national economic burden of rare disease in the United States in 2019 breakdown → 2022 ·Orphanet Journal of Rare Diseases ·(unknown), Inna Cintina, Anne Pariser, Elisabeth Oehrlein, Jamie Sullivan, Annie Kennedy	98
9	Stakeholder-Engaged Derivation of Patient-Informed Value Elements 2020 ·Patient ·Susan dosReis, (unknown), (unknown), Annie Kennedy, (unknown), Chengchen Zhang, Julia F. Slejko	20
10	Duchenne Muscular Dystrophy Newborn Screening: Evaluation of a New GSP® Neonatal Creatine Kinase-MM Kit in a US and Danish Population 2019 ·International Journal of Neonatal Screening ·(unknown), Michele A. Lloyd-Puryear, David M. Hougaard, (unknown), (unknown), Ville Laitala, (unknown), Kristin Skogstrand, Annie Kennedy, (unknown), (unknown), Teemu Korpimäki	23
11	Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan breakdown → 2018 ·The Lancet Neurology ·David J. Birnkrant, K. Bushby, Carla Bann, Susan Apkon, Angela Glover Blackwell, Mary K. Colvin, Linda Cripe, (unknown), Annie Kennedy, Kathi Kinnett, James Naprawa, Garey Noritz, James Poysky, Natalie Street, Christina Trout, David R. Weber, Leanne M. Ward	278
12	Health Care Transition Experiences of Males with Childhood-onset Duchenne and Becker Muscular Dystrophy: Findings from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) Health Care Transitions and Other Life Experiences Survey 2018 ·PLoS Currents ·Pangaja Paramsothy, (unknown), Molly M. Lamb, Kathi Kinnett, (unknown), Michele Yang, Joyce Oleszek, Shree Pandya, Annie Kennedy, (unknown), Deborah Fox, Daniel W. Sheehan	8
13	Duchenne Muscular Dystrophy Newborn Screening, a Case Study for Examining Ethical and Legal Issues for Pilots for Emerging Disorders: Considerations and Recommendations 2018 ·International Journal of Neonatal Screening ·Michele A. Lloyd-Puryear, Thomas O. Crawford, Amy Brower, (unknown), Tracy L. Trotter, Edward B. Goldman, Aaron J. Goldenberg, R. Rodney Howell, Annie Kennedy, Michael S. Watson	5
14	A Transition Toolkit for Duchenne Muscular Dystrophy 2018 ·PEDIATRICS ·Christina Trout, Laura E. Case, Paula R. Clemens, (unknown), Garey Noritz, (unknown), Kathryn R. Wagner, Elizabeth Vroom, Annie Kennedy	18
15	A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy 2017 ·International Journal of Neonatal Screening ·Samiah Al-Zaidy, Michele A. Lloyd-Puryear, Annie Kennedy, Verónica López, Jerry R. Mendell	12
16	Promoting meaningful clinical trial outcome measures for Duchenne muscular dystrophy 2016 ·Neuromuscular Disorders ·Holly L. Peay, Annie Kennedy, Ryan Fischer, (unknown), (unknown)	4
17	Muscular Dystrophy Association U.S. Neuromuscular Disease Registry - Preliminary Findings (P7.008) 2014 ·Neurology ·(unknown), Joline Dalton, Valerie Cwik, Annie Kennedy, (unknown), Jane Larkindale, Alan H. Beggs, Joshua O. Benditt, James D. Berry, Thomas O. Crawford, (unknown), Rachel Richesson, Jeffrey Rosenfeld, Carly E. Siskind, Kevin M. Flanigan	1
18	Cost of illness for neuromuscular diseases in the U.S 2014 ·Jane Larkindale, Wenya Yang, Paul F. Hogan, Carol Simon, Yiduo Zhang, Anjali Jain, (unknown), Annie Kennedy, Valerie Cwik	1
19	Cost of illness for neuromuscular diseases in the United States 2013 ·Muscle & Nerve ·Jane Larkindale, Wenya Yang, Paul F. Hogan, Carol Simon, Yiduo Zhang, Anjali Jain, (unknown), Annie Kennedy, Valerie Cwik	111
20	Desert Services that Work: Year One Research Report 2009 ·Queensland's institutional digital repository (The University of Queensland) ·Mark Moran, M. Anda, (unknown), Annie Kennedy, (unknown), (unknown), (unknown), Paul Memmott, Richard Mulgan, (unknown), Patrick Sullivan, Deirdre Tedmanson, Alyson Wright, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact